|
|
|
|
|
by qwerty85344324i
3958 days ago
|
|
Serious question for anyone opposes this. What incentive would pharma companies have to publish their secret formulas if Indian generics simply take the IP and drastically undercut prices, preventing the pharma companies from making any profit on the billions they invested in their research? What would compel these pharma companies to invest in any further research? |
|
1. Research does not get funded unless there is a commercial market for the drug. This leads to overfunding of maintenance treatments of chronic diseases like diabetes, because they are widespread and never really go away. Meanwhile, the system does not incentivize investment in things like antibiotics (because the next wide-spectrum antibiotic that gets developed will likely be force-licensed for public health interests).
2. For the vast majority of life-threatening diseases that anyone is likely to catch, the most effective drugs are already off-patent. Unless you can significantly improve outcomes, how can you compete with a generic that works 95% as well as your new drug?
3. The only country currently willing to pay sticker price for pharmaceuticals is the US. Every other country negotiates prices down to a fraction of what the US pays. The idea of a month worth of pills costing $400 is unheard of outside the US. So US citizens are either directly subsidizing the cheap drugs for the rest of the world, or we're getting taken for a ride.
4. The majority of the cost of developing a drug comes in the clinical trial phases. This cost is the same for any drug -- and most of this is marketing budget. Studies are designed to have specific outcomes so they can be listed as bullet points on information sheets given to doctors -- doctors are smart, but they're busy, so if you can do a study saying that "outcomes in high-risk patients were improved by 30% over the leading treatment", the doctors will never look to see what high-risk patients means, whether the study was done correctly, or even what an improved outcome looks like for those patients. Never mind you may have done the study 8 times and this outcome was only observed once.
Pharma is broken. Our current pharma industry is geared towards "lifecycle" drugs that alleviate symptoms rather than fixing any underlying problems.